ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Aug 15, 2017 20:00 JST
Source:
Alset International Ltd
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances
SINGAPORE, Aug 15, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.
3F (Functional Fragrance Formulation) is a suite of functional fragrances being developed. The first product, 3F Mosquito, is made of specialised oils sourced from botanicals which mosquitoes avoid. 3F Mosquito was designed with an objective to identify, then create a suitable formula that was pleasant, yet excels in providing layers of protection against mosquitoes.
Daryl Thompson, Global BioLife Director of Scientific Initiatives, leads the 3F research. "The specialised oils in 3F Mosquito are scientifically proven to affect a mosquito's receptors, essentially making the mosquito blind to your presence," says Thompson.
In addition to 3F Mosquito, Global BioLife and Chemia are developing fragrances as additives for use in laundry detergents, shampoos and lotions, providing additional layers of protection against mosquitoes, and developing advanced coatings for industrial and medical applications.
"Biomedical science has become increasingly vital. Global BioLife is taking steps toward providing solutions to issues that have plagued the biomedical field for decades. This working collaboration marks a first steps in actively changing the game of healthcare," said Chan Heng Fai, SeD Executive Chairman and Chief Executive Officer, and a Global BioLife Director.
Global BioLife is an 80%-held subsidiary of SeD wholly-owned Global BioMedical Inc. The remaining shareholding in Global BioLife is held by Thompson's GRDG Sciences LLC and Australia Securities Exchange-listed Holista CollTech Limited, in equal proportions of 10% each.
About Chemia Corporation
Chemia Corporation provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. Thomas A. Meyer is the Vice-President of Innovation and Sustainability. For further information, please visit www.chemiacorp.com.
About GRDG Sciences LLC
GRDG Sciences LLC is a natural products discovery drug research company incorporated in Florida, USA. The Company was set up by natural products scientist Daryl Thompson. Thompson is a biochemist, nominated for the Nobel Prize in 2015 and 2016 for his research in pandemic technology.
About Holista CollTech Ltd
Holista CollTech is incorporated in Australia and listed on the Australian Securities Exchange. A research-driven biotechnology company, Holista focuses on research and development of product in the natural products space. Founder and Chief Executive Officer Dr Rajen Manicka holds a PhD in Holistic Medicine and a Masters of Business Administration. For further information, please visit www.holistaco.com.
About Singapore eDevelopment Ltd
Singapore eDevelopment Ltd (SeD) was incorporated on 9 Sept 2009, and listed by SGX Catalist (SGX:SGE) in July 2010. SeD is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.
Issued for the Company:
WeR1 Consultants Pte Ltd
Ian Lau
Tel : +65 6737 4844
Email:
ianlau@wer1.net
Source: Alset International Ltd
Sectors: Healthcare & Pharm, Funds & Equities, Cosmetics, Spec.Chem
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Hitachi High-Tech Launches DCR Etch System 9060 Series, Supporting Isotropic Etching of Advanced 3D Devices at the Atomic Level
Nov 28, 2024 11:31 JST
MHI Delivers Final Trainset of Automated Guideway Transit System "2020 Series" to Saitama New Urban Transit
Nov 28, 2024 10:08 JST
TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market
Nov 27, 2024 05:53 JST
TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST
Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST
TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025
Nov 25, 2024 17:10 JST
Toyota Submits Progress Report on Recurrence Prevention Measures
Nov 25, 2024 15:43 JST
TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market
Nov 25, 2024 15:00 JST
MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant
Nov 25, 2024 14:18 JST
Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship
Nov 25, 2024 11:55 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
More Latest Release >>
Related Release
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities
March 23 2022 09:00 JST
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
February 21 2022 12:00 JST
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
More Press release >>